Each week we highlight five things affecting the life sciences industry. Here’s the latest. FTC appointments possibly signal decreased scrutiny on biopharma M&A President-elect Donald Trump’s nomination of Andrew Ferguson and Mark Meador to the Federal Trade Commission signals a potential shift toward a more business-friendly antitrust approach, focusing on … … READ MORE >
FTC
5 things to know in life sciences: Week of May 15, 2023
This week we look at how changes to accelerated approvals at the Food and Drug Administration are affecting drug approvals. Also, there is news of CVS’s foray into clinical trials, the end of the public health emergency for COVID-19, and the costs of the Supreme Court not hearing a case involving generic drugs. … READ MORE >
Drug pricing and health care innovation could benefit from Biden’s latest executive order
A recent executive order promoting competition in the American economy could have significant ramifications for health care systems. … READ MORE >
5 things to know in life sciences: Week of June 14
From tools to support decentralized clinical trials to new efforts to reduce systemic racism in medical research, each week we highlight five things you need to know about in the life sciences industry. … READ MORE >